Pioglitazone - Takeda

Drug Profile

Pioglitazone - Takeda

Alternative Names: Actos; AD-4833; Glustin; PGZ; Piozone; U 72107; U 72107A; U 72107E; Zactos

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Duke University Medical Center; Eli Lilly; Glenmark Pharmaceuticals Ltd; Novo Nordisk; Piramal Enterprises; Takeda; Takeda Pharmaceuticals USA; Tianjin Takeda; Zinfandel Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Alzheimer's disease
  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Atherosclerosis; Multiple sclerosis

Most Recent Events

  • 25 Jan 2018 Takeda and Zinfandel Pharmaceuticals terminates the phase III TOMMORROW trial based on a planned interim futility analysis in Alzheimer's disease in USA, United Kingdom, Germany, Italy, Switzerland and Australia (PO) (NCT01931566)
  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2016 Takeda and Zinfandel Pharmaceuticals complete enrolment in the phase III TOMMORROW trial in Alzheimer's disease in USA, the United Kingdom, Germany, Switzerland and Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top